LeBoeuf SE

Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with LeBoeuf

Contact LeBoeuf, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.

Claim your profile

Articles

Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in KEAP1 mutant lung cancer

Jun 27, 2023 |

By Huang SM, Wu WL, LeBoeuf SE, Blum JLE

| ncbi.nlm.nih.gov

This is a preprint. It has not yet been peer reviewed by a journal. The National Library of Medicine is running a pilot to include preprints that result from research funded by NIH in PMC and PubMed. bioRxiv. Display options Format doi: 10.1101/2023.06.27.546750.

Open in Who Shared

See all 1 articles

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.

Claim your profile

Get in touch with LeBoeuf

Contact LeBoeuf, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Overview

Use Cases

Capabilities

Industries

Library

Commmunity

Customers

LeBoeuf SE

Get in touch with LeBoeuf

Actions

Is this you?

Articles

Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in KEAP1 mutant lung cancer

Actions

Is this you?

Get in touch with LeBoeuf